OBJECTIVE

To test the hypothesis that maternal gestational diabetes increases cardiovascular risk markers in Indian children.

RESEARCH DESIGN AND METHODS

Anthropometry, blood pressure, and glucose/insulin concentrations were measured in 514 children at 5 and 9.5 years of age (35 offspring of diabetic mothers [ODMs], 39 offspring of diabetic fathers [ODFs]). Children of nondiabetic parents were control subjects.

RESULTS

At age 9.5 years, female ODMs had larger skinfolds (P < 0.001), higher glucose (30 min) and insulin concentrations, and higher homeostasis model assessment (HOMA) of insulin resistance and systolic blood pressure (P < 0.05) than control subjects. Male ODMs had higher HOMA (P < 0.01). Associations were stronger than at age 5 years. Female ODFs had larger skinfolds and male ODFs had higher HOMA (P < 0.05) than control subjects; associations were weaker than for ODMs. Associations between outcomes in control subjects and parental BMI, glucose, and insulin concentrations were similar for mothers and fathers.

CONCLUSIONS

The intrauterine environment experienced by ODMs increases diabetes and cardiovascular risk over genetic factors; the effects strengthen during childhood.

Offspring of diabetic mothers (ODMs) are at an increased risk for obesity/adiposity, glucose intolerance, and increased blood pressure even during childhood (1,,4). These risks are higher compared with offspring of diabetic fathers (ODFs), suggesting intrauterine programming by maternal hyperglycemia (1). Even in nondiabetic pregnancies, higher maternal glycaemia is associated with neonatal and postnatal adiposity (5,6). In a cohort of 5-year-old Indian children, maternal gestational diabetes (GDM), but not paternal diabetes, was associated with increased adiposity and insulin concentrations in the female offspring (7). The children were reexamined at 9–10 years of age.

During 1997–1998, 630 women who completed an oral glucose tolerance test at 30 ± 2 weeks' gestation delivered live, normal babies at the Holdsworth Memorial Hospital, Mysore, India (7); 41 women had GDM (Carpenter-Coustan criteria) (8).

At age 5 and 9.5 years, weight (Salter, Kent, U.K.), height (Microtoise; CMS Instruments, Cambridge, U.K.), mid–upper-arm circumference, and triceps and subscapular skinfolds (Harpenden calipers; CMS Instruments) were measured in 514 children available for follow-up (35 ODMs). Systolic and diastolic blood pressure were measured in the left arm (Dinamap; Criticon). Blood samples were collected fasting and 30 and 120 min after a 1.75 g/kg body wt glucose load, after an overnight fast.

Plasma glucose, triglycerides, and HDL cholesterol concentrations were measured by standard enzymatic methods (Alcyon 3000 autoanalyzer; Abbott Laboratories). Insulin was measured using a time-resolved, fluoroimmunoassay (DELFIA) method (PerkinElmer Life 186 and Analytical Sciences, Wallac Qy, Turku, Finland). Interassay coefficients of variations were 12.5% at <45 pmol/l and <10% at ≥45 pmol/l.

Paternal diabetes status was assessed using fasting glucose at the 5-year follow-up. Offspring of non-GDM mothers and diabetic fathers were designated ODFs (n = 39). Offspring of nondiabetic parents were designated control subjects (n = 381). During 6–10 years of age, physical activity was measured in 408 children using Actigraph accelerometers (AM7164/GT1M; MTI) that measure movement in the vertical plane as counts. Detailed methodology is described elsewhere (9). Pubertal growth was assessed at age 9.5 years, using breast development in girls and testicular volume in boys (10). The hospital ethical committee approved the study; the parents and children gave informed consent/assent.

Statistical methods

Insulin resistance was estimated using the homeostasis model assessment (HOMA) equation (11). Maternal plasma glucose area under the curve (GAUC) and insulin area under the curve (IAUC) were calculated using the trapezoid rule (12). Offspring BMI, subscapular skinfolds, insulin concentrations, and HOMA were log transformed to normality. Differences between ODMs, ODFs, and control subjects were assessed using t tests. Adjustments for parental BMI were performed using multiple regression. Parental BMI, insulin, and glucose variables, expressed as SD scores were used in linear regression models to test the associations in control children.

At age 9.5 years, female ODMs were larger in all anthropometric measurements, except height, than control subjects (Table 1), even after adjusting for maternal BMI (P < 0.05). The difference in skinfold measurement between ODMs and control female subjects increased with age (online appendix Fig. A1, available at http://care.diabetesjournals.org/cgi/content/full/dc09-1393/DC1). Plasma 30-min glucose concentrations, insulin concentrations at all time points, HOMA, and systolic blood pressure were higher in female ODMs, and male ODMs had higher fasting insulin and HOMA, than control subjects. The differences were greater at age 9.5 years than at age 5 years (Table 1). Associations with 0-min and 120-min insulin concentrations, HOMA, and systolic blood pressure in girls became nonsignificant after adjusting for current BMI. The interaction term sex × maternal GDM status was statistically significant for skinfold measurements and 30-min insulin (P < 0.05).

Table 1

Anthropometry, glucose, insulin, and lipid concentrations and blood pressure in ODMs, control subjects, and ODFs, at the age of 5 and 9.5 years

Girls
Boys
Follow-up at 9.5 years
Follow-up at 9.5 years
ODMs (n = 23)P1Control subjects (n = 191)P2ODFs (n = 19)ODMs (n = 12)P1Control subjects (n = 190)P2ODFs (n = 20)
Anthropometry   
    Height (cm) 132.2 ± 6.3 0.2 130.4 ± 5.9 0.6 129.7 ± 6.1 130.8 ± 6.3 0.8 131.3 ± 5.5 0.4 132.3 ± 5.6 
    BMI (kg/m216.4 (14.8–17.8) <0.001 14.3 (13.3–15.4) 0.9 14.3 (13.1–15.6) 15.2 (13.8–16.6) 0.07 14.2 (13.4–15.4) 0.4 14.8 (13.9–15.5) 
    MUAC (cm) 20.1 ± 2.3 <0.001 17.9 ± 2.0 0.8 18.0 ± 1.9 19.1 ± 1.9 0.04 17.9 ± 2.0 0.4 18.3 ± 1.6 
    Triceps (mm) 14.9 ± 4.7 <0.001 10.5 ± 3.1 0.2 11.4 ± 2.7 10.3 ± 3.6 0.1 8.8 ± 3.2 0.9 8.9 ± 2.2 
    Subscapular (mm) 14.1 (8.2–17.3) <0.001 7.6 (6.2–9.4) 0.006 8.4 (7.5–12.9) 7.15 (5.8–8.8) 0.2 6.0 (5.3–7.9) 0.7 6.3 (5.4–8.1) 
Glucose/insulin           
    Glucose0 (mmol/l) 4.6 ± 0.4 0.7 4.7 ± 0.4 0.3 4.8 ± 0.5 4.7 ± 0.4 0.6 4.7 ± 0.4 0.9 4.7 ± 0.5 
    Glucose30 (mmol/l) 7.7 ± 1.0 0.002 6.9 ± 1.3 0.2 6.5 ± 1.2 6.8 ± 1.3 0.9 6.7 ± 1.3 0.5 6.5 ± 1.6 
    Glucose120 (mmol/l) 5.4 ± 0.9 0.2 5.2 ± 0.9 0.8 5.1 ± 0.8 5.1 ± 0.7 0.9 5.0 ± 1.0 0.999 5.0 ± 1.2 
    Insulin0 (pmol/l) 35 (25–48) 0.003 25 (18–37) 0.95 26 (18–34) 32.1 (26.3–40.1) 0.001 17 (11–27) 0.01 22 (15–34) 
    Insulin30 (pmol/l) 432 (302–597) <0.001 261 (167–418) 0.6 246 (157–380) 197 (124–392) 0.99 194 (118–338) 0.9 162 (137–342) 
    Insulin120 (pmol/l) 172 (101–244) 0.006 118 (80–176) 0.3 116 (78–150) 95 (45–174) 0.6 78 (52–130) 0.3 108 (67–158) 
Cardiovascular disease risk factors           
    Insulin resistance (HOMA) 1.2 (0.8–1.6) 0.006 0.9 (0.63–1.30) 0.95 0.9 (0.6–1.2) 1.1 (0.9–1.4) 0.002 0.6 (0.36–0.94) 0.03 0.8 (0.5–1.2) 
    Triglycerides (mmol/l) 1.1 ± 0.5 0.2 1.0 ± 0.4 0.5 0.9 ± 0.4 0.8 ± 0.3 0.6 0.8 ± 0.3 0.9 0.9 ± 0.3 
    HDL cholesterol (mmol/l) 1.0 ± 0.2 0.2 1.1 ± 0.2 0.4 1.0 ± 0.2 1.2 ± 0.3 0.4 1.1 ± 0.2 0.7 1.1 ± 0.2 
    Systolic blood pressure (mmHg) 103.8 ± 8.0 0.02 99.4 ± 8.5 0.8 100.0 ± 8.3 106 ± 12.0 0.2 101.9 ± 8.9 0.8 102.5 ± 7.3 
    Diastolic blood pressure (mmHg) 59.8 ± 4.8 0.09 57.9 ± 6.6 0.9 57.8 ± 6.6 60.3 ± 7.6 0.4 58.6 ± 6.9 0.9 58.4 ± 7.5 
Physical activity           
    Total counts (n388,977 ± 91,730 0.3 415,458 ± 126,925 0.7 399,763 ± 135,255 443,025 ± 87,648 0.3 482,348 ± 126,790 0.4 514,960 ± 212,854 
    Vigorous activity (min) 15.8 ± 11.3 0.2 19.1 ± 12.5 0.8 19.9 ± 15.1 20.9 ± 10.9 0.2 27.2 ± 14.2 0.4 30.9 ± 18.9 
Girls
Boys
Follow-up at 9.5 years
Follow-up at 9.5 years
ODMs (n = 23)P1Control subjects (n = 191)P2ODFs (n = 19)ODMs (n = 12)P1Control subjects (n = 190)P2ODFs (n = 20)
Anthropometry   
    Height (cm) 132.2 ± 6.3 0.2 130.4 ± 5.9 0.6 129.7 ± 6.1 130.8 ± 6.3 0.8 131.3 ± 5.5 0.4 132.3 ± 5.6 
    BMI (kg/m216.4 (14.8–17.8) <0.001 14.3 (13.3–15.4) 0.9 14.3 (13.1–15.6) 15.2 (13.8–16.6) 0.07 14.2 (13.4–15.4) 0.4 14.8 (13.9–15.5) 
    MUAC (cm) 20.1 ± 2.3 <0.001 17.9 ± 2.0 0.8 18.0 ± 1.9 19.1 ± 1.9 0.04 17.9 ± 2.0 0.4 18.3 ± 1.6 
    Triceps (mm) 14.9 ± 4.7 <0.001 10.5 ± 3.1 0.2 11.4 ± 2.7 10.3 ± 3.6 0.1 8.8 ± 3.2 0.9 8.9 ± 2.2 
    Subscapular (mm) 14.1 (8.2–17.3) <0.001 7.6 (6.2–9.4) 0.006 8.4 (7.5–12.9) 7.15 (5.8–8.8) 0.2 6.0 (5.3–7.9) 0.7 6.3 (5.4–8.1) 
Glucose/insulin           
    Glucose0 (mmol/l) 4.6 ± 0.4 0.7 4.7 ± 0.4 0.3 4.8 ± 0.5 4.7 ± 0.4 0.6 4.7 ± 0.4 0.9 4.7 ± 0.5 
    Glucose30 (mmol/l) 7.7 ± 1.0 0.002 6.9 ± 1.3 0.2 6.5 ± 1.2 6.8 ± 1.3 0.9 6.7 ± 1.3 0.5 6.5 ± 1.6 
    Glucose120 (mmol/l) 5.4 ± 0.9 0.2 5.2 ± 0.9 0.8 5.1 ± 0.8 5.1 ± 0.7 0.9 5.0 ± 1.0 0.999 5.0 ± 1.2 
    Insulin0 (pmol/l) 35 (25–48) 0.003 25 (18–37) 0.95 26 (18–34) 32.1 (26.3–40.1) 0.001 17 (11–27) 0.01 22 (15–34) 
    Insulin30 (pmol/l) 432 (302–597) <0.001 261 (167–418) 0.6 246 (157–380) 197 (124–392) 0.99 194 (118–338) 0.9 162 (137–342) 
    Insulin120 (pmol/l) 172 (101–244) 0.006 118 (80–176) 0.3 116 (78–150) 95 (45–174) 0.6 78 (52–130) 0.3 108 (67–158) 
Cardiovascular disease risk factors           
    Insulin resistance (HOMA) 1.2 (0.8–1.6) 0.006 0.9 (0.63–1.30) 0.95 0.9 (0.6–1.2) 1.1 (0.9–1.4) 0.002 0.6 (0.36–0.94) 0.03 0.8 (0.5–1.2) 
    Triglycerides (mmol/l) 1.1 ± 0.5 0.2 1.0 ± 0.4 0.5 0.9 ± 0.4 0.8 ± 0.3 0.6 0.8 ± 0.3 0.9 0.9 ± 0.3 
    HDL cholesterol (mmol/l) 1.0 ± 0.2 0.2 1.1 ± 0.2 0.4 1.0 ± 0.2 1.2 ± 0.3 0.4 1.1 ± 0.2 0.7 1.1 ± 0.2 
    Systolic blood pressure (mmHg) 103.8 ± 8.0 0.02 99.4 ± 8.5 0.8 100.0 ± 8.3 106 ± 12.0 0.2 101.9 ± 8.9 0.8 102.5 ± 7.3 
    Diastolic blood pressure (mmHg) 59.8 ± 4.8 0.09 57.9 ± 6.6 0.9 57.8 ± 6.6 60.3 ± 7.6 0.4 58.6 ± 6.9 0.9 58.4 ± 7.5 
Physical activity           
    Total counts (n388,977 ± 91,730 0.3 415,458 ± 126,925 0.7 399,763 ± 135,255 443,025 ± 87,648 0.3 482,348 ± 126,790 0.4 514,960 ± 212,854 
    Vigorous activity (min) 15.8 ± 11.3 0.2 19.1 ± 12.5 0.8 19.9 ± 15.1 20.9 ± 10.9 0.2 27.2 ± 14.2 0.4 30.9 ± 18.9 
Follow-up at 5 yearsFollow-up at 5 years
    Triceps skinfold (cm) 10.1 (7.8–10.6) 0.007 8.0 (6.8–9.3) 0.6 8.3 (7.2–9.3) 7.2 (5.9–8.4) 0.7 7.0 (6.2–8.1) 0.2 7.6 (6.7–8.7) 
    Subscapular skinfold (cm) 7.8 (5.8–8.7) 0.005 5.9 (5.0–7.5) 0.7 6.0 (5.3–7.9) 5.2 (4.6–6.2) 0.9 5.2 (4.7–6.1) 0.3 5.6 (5.0–6.7) 
    Glucose120 (mmol/l) 6.1 ± 1.2 0.2 5.8 ± 0.9 0.4 6.0 ± 1.0 6.0 ± 0.6 0.9 6.0 ± 1.0 0.006 5.3 ± 1.1 
    Insulin30 (pmol/l) 217 (154–300) 0.01 172 (104–228) 0.4 164 (126–233) 168 (84–242) 0.8 117 (73–207) 0.5 157 (88–255) 
    Insulin120 (pmol/l) 114 (74–192) 0.049 92 (63–131) 0.1 83 (36–129) 85 (63–156) 0.5 80 (53–118) 0.01 50 (26–80.0) 
    Insulin resistance (HOMA) 1.1 (0.6–1.3) 0.2 0.8 (0.5–1.2) 0.7 0.8 (0.6–1.2) 1.0 (0.4–1.1) 0.5 0.7 (0.4–1.0) 0.2 0.7 (0.4–1.3) 
    Systolic blood pressure (mmHg) 99.0 ± 8.2 0.08 95.8 ± 8.1 0.8 95.4 ± 9.4 101.2 ± 8.7 0.1 97.2 ± 8.9 0.6 98.2 ± 6.1 
Follow-up at 5 yearsFollow-up at 5 years
    Triceps skinfold (cm) 10.1 (7.8–10.6) 0.007 8.0 (6.8–9.3) 0.6 8.3 (7.2–9.3) 7.2 (5.9–8.4) 0.7 7.0 (6.2–8.1) 0.2 7.6 (6.7–8.7) 
    Subscapular skinfold (cm) 7.8 (5.8–8.7) 0.005 5.9 (5.0–7.5) 0.7 6.0 (5.3–7.9) 5.2 (4.6–6.2) 0.9 5.2 (4.7–6.1) 0.3 5.6 (5.0–6.7) 
    Glucose120 (mmol/l) 6.1 ± 1.2 0.2 5.8 ± 0.9 0.4 6.0 ± 1.0 6.0 ± 0.6 0.9 6.0 ± 1.0 0.006 5.3 ± 1.1 
    Insulin30 (pmol/l) 217 (154–300) 0.01 172 (104–228) 0.4 164 (126–233) 168 (84–242) 0.8 117 (73–207) 0.5 157 (88–255) 
    Insulin120 (pmol/l) 114 (74–192) 0.049 92 (63–131) 0.1 83 (36–129) 85 (63–156) 0.5 80 (53–118) 0.01 50 (26–80.0) 
    Insulin resistance (HOMA) 1.1 (0.6–1.3) 0.2 0.8 (0.5–1.2) 0.7 0.8 (0.6–1.2) 1.0 (0.4–1.1) 0.5 0.7 (0.4–1.0) 0.2 0.7 (0.4–1.3) 
    Systolic blood pressure (mmHg) 99.0 ± 8.2 0.08 95.8 ± 8.1 0.8 95.4 ± 9.4 101.2 ± 8.7 0.1 97.2 ± 8.9 0.6 98.2 ± 6.1 

Data are means ± SD or median (interquartile range). P1 for the difference between ODMs and control subjects; P2 for the difference between ODFs and control subjects.

Physical activity counts were lower in ODMs than control children (Table 1) (P = 0.01, sexes combined). They also spent less time vigorously active (≥3,000 counts/min; P = 0.03, sexes combined). Female ODMs were more likely to be in the second and third stages of breast development (43% [n = 10] vs. 24% [n = 45] in control girls; P = 0.01), but among boys, testicular volume was similar in all groups.

Female ODFs had larger subscapular skinfolds, and male ODFs had higher fasting insulin concentrations and HOMA than control children at age 9.5 years (Table 1). These differences became nonsignificant in male subjects after adjusting for paternal BMI. There were no significant sex interactions.

In the control children at age 9.5 years, maternal (gestational) and paternal BMI (5-year follow-up) were positively related to subscapular skinfolds (β = 0.08 [95% CI 0.05–0.12] and β = 0.09 [0.06–0.12], respectively; P < 0.001 adjusted for age and sex) and HOMA (β = 0.09 [0.03–0.15]; P < 0.01). Maternal IAUC was positively related to subscapular skinfolds (β = 0.10 [0.06–0.14]; P < 0.001), HOMA (β = 0.09 [0.02–0.16]), and systolic blood pressure (β =1.17 [0.18–2.16]; P = 0.02). Paternal fasting insulin was related to subscapular skinfolds (β = 0.07 [0.03–0.11]) and HOMA (β = 0.11 [0.04–0.17]). Maternal GAUC and paternal fasting glucose were unrelated to offspring adiposity and HOMA.

In a sample of normal children in India, ODMs, particularly girls, were more adipose and had higher systolic blood pressure and insulin resistance compared with control children at age 9.5 years. Our findings are consistent with earlier studies among Pima Indian and Caucasian children (1,,4). The differences between ODMs and control subjects were greater at age 9.5 years than at age 5 years. Physical activity was lower in the ODMs, and female ODMs were at an advanced pubertal stage than control subjects at age 9.5 years. Sedentary behavior and advanced maturity may be aggravating factors.

The different associations in boys and girls may be related to fewer boys than girls in our ODM group. Alternatively, female subjects may be more susceptible to adverse lifestyle behaviors in a shared environment due to their proximity to mothers in this population.

Though paternal diabetes was associated with higher offspring adiposity and insulin resistance, associations with maternal diabetes were stronger and related to more outcomes, suggesting that intrauterine exposure to hyperglycemia has additional effects apart from those related to genetic predisposition. The associations between child outcomes and parental BMI, glucose, and insulin concentrations in the absence of diabetes were similar for mothers and fathers; these could be mediated by genes or by shared family lifestyle/environment. Thus, our study does not suggest an additional independent effect of intrauterine exposure to higher maternal glycemia in the nondiabetic range.

Maternal diabetes is a strong determinant of adiposity and clustering of cardiovascular risk factors in Indian children. Since GDM now affects 5–20% of urban Indian pregnant women (7,13), this may contribute to the escalating prevalence of type 2 diabetes in this region.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This study was funded by the Parthenon Trust, Switzerland; the Wellcome Trust, U.K.; and the Medical Research Council, U.K.

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 6th World Congress on Developmental Origins of Health and Disease, Santiago, Chile, 19–22 November 2009.

We are grateful to the families and hospital staff, the research team, Jane Pearce, Patsy Coakley, and Sneha-India for their support. We thank Dr. C.S. Yajnik and staff (KEM Hospital, Pune) for biochemical assays and Dr. U. Ekelund (MRC Epidemiology Unit, Cambridge, U.K.) for help with accelerometers.

1.
Dabelea
D
.
The predisposition to obesity and diabetes in offspring of diabetic mothers
.
Diabetes Care
2007
; 
30
(
Suppl. 2
):
S169
S174
2.
Bunt
JC
,
Tataranni
PA
,
Salbe
AD
.
Intrauterine exposure to diabetes is a determinant of HbA1c and systolic blood pressure in Pima Indian children
.
J Clin Endocrinol Metab
2005
; 
90
:
3225
3229
3.
Silverman
BL
,
Rizzo
T
,
Green
OC
,
Cho
NH
,
Winter
RJ
,
Ogata
ES
,
Richards
GE
,
Metzger
BE
.
Long-term prospective evaluation of offspring of diabetic mothers
.
Diabetes
1991
; 
40
(
Suppl. 2
):
121
125
4.
Wright
CS
,
Rifas-Shiman
SL
,
Rich-Edwards
JW
,
Taveras
EM
,
Gillman
MW
,
Oken
E
.
Intrauterine exposure to gestational diabetes, child adiposity, and blood pressure
.
Am J Hypertens
2009
; 
22
:
215
220
5.
The HAPO Study Cooperative Research Group.
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics
.
Diabetes
2009
; 
58
:
453
459
6.
Hillier
TA
,
Pedula
KL
,
Schmidt
MM
,
Mullen
JA
,
Charles
M
,
Pettitt
DJ
.
Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia
.
Diabetes Care
2007
; 
30
:
2287
2292
7.
Krishnaveni
GV
,
Hill
JC
,
Leary
SD
,
Veena
SR
,
Saperia
J
,
Saroja
A
,
Karat
SC
,
Fall
CH
.
Anthropometry, glucose tolerance, and insulin concentrations in Indian children: relationships to maternal glucose and insulin concentrations during pregnancy
.
Diabetes Care
2005
; 
28
:
2919
2925
8.
Carpenter
MW
,
Coustan
DR
.
Criteria for screening tests for gestational diabetes
.
Am J Obstet Gynecol
1982
; 
159
:
768
773
9.
Krishnaveni
GV
,
Mills
IC
,
Veena
SR
,
Wootton
SA
,
Wills
AK
,
Coakley
PJ
.
Accelerometers for measuring physical activity behavior in Indian children
.
Indian Pediatr
2009
[
Epub ahead of print
]
10.
Tanner
JM
.
Growth in Adolescence
. 2nd ed.
Oxford, England
,
Blackwell Scientific Publications
,
1962
11.
Matthews
DR
,
Hosker
JP
,
Rudenski
AS
,
Naylor
BA
,
Treacher
DF
,
Turner
RC
.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man
.
Diabetologia
1985
; 
28
:
412
419
12.
Tai
MM
.
A mathematical model for the determination of total area under glucose tolerance and other metabolic curves
.
Diabetes Care
1994
; 
17
:
152
154
13.
Seshiah
V
,
Balaji
V
,
Balaji
MS
,
Sanjeevi
CB
,
Green
A
.
Gestational diabetes mellitus in India
.
J Assoc Physicians India
2004
; 
52
:
707
711
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Supplementary data